Therapeutic strategies for severe alcoholic hepatitis

Yoshinori Horie, Yoshiyuki Yamagishi, Hirotoshi Ebinuma, Toshifumi Hibi

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background and aims: Severe alcoholic hepatitis (SAH) is an inflammatory response with multiple morbidity factors like leucocytosis, hepatomegaly, renal failure, hepatic encephalopathy, endotoxemia, and has a high mortality rate. Accordingly, identifying therapeutic interventions that can support prognosis is the goal of research. Methods: Questionnaires were sent to 1234 medical institutions asking for information on patients with SAH during 2004 to 2008 including patients' demography, disease profile and the therapeutic interventions patients had received during hospitalization. Results: Twenty-nine hospitals had treated SAH patients, and provided full demographic data on 62 patients. Twenty-seven patients had received no treatment, 10 patients had received granulocytes/monocytes apheresis (GMA) to deplete elevated myeloid linage leucocytes, the rest had received one or more of the following treatments, corticosteroids, plasma exchange (PE) and haemodialysis (HD). Further, 23 patients had died and 39 had survived within 100 days of hospitalization. Serum creatinine (Cr) was higher in patients who had died vs patients who had survived (P=0.026). Likewise, patients with white blood cells (WBC)≥10 4/μL had higher mortality rate vs patients with WBC<10 4/μL (P=0.039). GMA in patients with WBC≥10 4/μL showed 100% prognosis vs patients with WBC≥10 4/μL who did not receive GMA (P=0.0007). Corticosteroids, PE and HD did not significantly impact prognosis of SAH patients. Conclusions: Our perception is that, patients with elevated myeloid leucocytes benefit most from GMA, while PE appears to support patients with coagulation deficiency or high plasma bilirubin and HD has indication in patients with high Cr.

Original languageEnglish
Pages (from-to)738-744
Number of pages7
JournalClinics and Research in Hepatology and Gastroenterology
Volume35
Issue number11
DOIs
Publication statusPublished - 2011 Nov

Fingerprint

Alcoholic Hepatitis
Blood Component Removal
Therapeutics
Granulocytes
Plasma Exchange
Monocytes
Leukocytes
Renal Dialysis
Creatinine
Adrenal Cortex Hormones
Hospitalization
Demography

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Therapeutic strategies for severe alcoholic hepatitis. / Horie, Yoshinori; Yamagishi, Yoshiyuki; Ebinuma, Hirotoshi; Hibi, Toshifumi.

In: Clinics and Research in Hepatology and Gastroenterology, Vol. 35, No. 11, 11.2011, p. 738-744.

Research output: Contribution to journalArticle

Horie, Yoshinori ; Yamagishi, Yoshiyuki ; Ebinuma, Hirotoshi ; Hibi, Toshifumi. / Therapeutic strategies for severe alcoholic hepatitis. In: Clinics and Research in Hepatology and Gastroenterology. 2011 ; Vol. 35, No. 11. pp. 738-744.
@article{35afb215c52a4e75bae6110939b583df,
title = "Therapeutic strategies for severe alcoholic hepatitis",
abstract = "Background and aims: Severe alcoholic hepatitis (SAH) is an inflammatory response with multiple morbidity factors like leucocytosis, hepatomegaly, renal failure, hepatic encephalopathy, endotoxemia, and has a high mortality rate. Accordingly, identifying therapeutic interventions that can support prognosis is the goal of research. Methods: Questionnaires were sent to 1234 medical institutions asking for information on patients with SAH during 2004 to 2008 including patients' demography, disease profile and the therapeutic interventions patients had received during hospitalization. Results: Twenty-nine hospitals had treated SAH patients, and provided full demographic data on 62 patients. Twenty-seven patients had received no treatment, 10 patients had received granulocytes/monocytes apheresis (GMA) to deplete elevated myeloid linage leucocytes, the rest had received one or more of the following treatments, corticosteroids, plasma exchange (PE) and haemodialysis (HD). Further, 23 patients had died and 39 had survived within 100 days of hospitalization. Serum creatinine (Cr) was higher in patients who had died vs patients who had survived (P=0.026). Likewise, patients with white blood cells (WBC)≥10 4/μL had higher mortality rate vs patients with WBC<10 4/μL (P=0.039). GMA in patients with WBC≥10 4/μL showed 100{\%} prognosis vs patients with WBC≥10 4/μL who did not receive GMA (P=0.0007). Corticosteroids, PE and HD did not significantly impact prognosis of SAH patients. Conclusions: Our perception is that, patients with elevated myeloid leucocytes benefit most from GMA, while PE appears to support patients with coagulation deficiency or high plasma bilirubin and HD has indication in patients with high Cr.",
author = "Yoshinori Horie and Yoshiyuki Yamagishi and Hirotoshi Ebinuma and Toshifumi Hibi",
year = "2011",
month = "11",
doi = "10.1016/j.clinre.2011.07.005",
language = "English",
volume = "35",
pages = "738--744",
journal = "Clinics and Research in Hepatology and Gastroenterology",
issn = "2210-7401",
publisher = "Elsevier Masson",
number = "11",

}

TY - JOUR

T1 - Therapeutic strategies for severe alcoholic hepatitis

AU - Horie, Yoshinori

AU - Yamagishi, Yoshiyuki

AU - Ebinuma, Hirotoshi

AU - Hibi, Toshifumi

PY - 2011/11

Y1 - 2011/11

N2 - Background and aims: Severe alcoholic hepatitis (SAH) is an inflammatory response with multiple morbidity factors like leucocytosis, hepatomegaly, renal failure, hepatic encephalopathy, endotoxemia, and has a high mortality rate. Accordingly, identifying therapeutic interventions that can support prognosis is the goal of research. Methods: Questionnaires were sent to 1234 medical institutions asking for information on patients with SAH during 2004 to 2008 including patients' demography, disease profile and the therapeutic interventions patients had received during hospitalization. Results: Twenty-nine hospitals had treated SAH patients, and provided full demographic data on 62 patients. Twenty-seven patients had received no treatment, 10 patients had received granulocytes/monocytes apheresis (GMA) to deplete elevated myeloid linage leucocytes, the rest had received one or more of the following treatments, corticosteroids, plasma exchange (PE) and haemodialysis (HD). Further, 23 patients had died and 39 had survived within 100 days of hospitalization. Serum creatinine (Cr) was higher in patients who had died vs patients who had survived (P=0.026). Likewise, patients with white blood cells (WBC)≥10 4/μL had higher mortality rate vs patients with WBC<10 4/μL (P=0.039). GMA in patients with WBC≥10 4/μL showed 100% prognosis vs patients with WBC≥10 4/μL who did not receive GMA (P=0.0007). Corticosteroids, PE and HD did not significantly impact prognosis of SAH patients. Conclusions: Our perception is that, patients with elevated myeloid leucocytes benefit most from GMA, while PE appears to support patients with coagulation deficiency or high plasma bilirubin and HD has indication in patients with high Cr.

AB - Background and aims: Severe alcoholic hepatitis (SAH) is an inflammatory response with multiple morbidity factors like leucocytosis, hepatomegaly, renal failure, hepatic encephalopathy, endotoxemia, and has a high mortality rate. Accordingly, identifying therapeutic interventions that can support prognosis is the goal of research. Methods: Questionnaires were sent to 1234 medical institutions asking for information on patients with SAH during 2004 to 2008 including patients' demography, disease profile and the therapeutic interventions patients had received during hospitalization. Results: Twenty-nine hospitals had treated SAH patients, and provided full demographic data on 62 patients. Twenty-seven patients had received no treatment, 10 patients had received granulocytes/monocytes apheresis (GMA) to deplete elevated myeloid linage leucocytes, the rest had received one or more of the following treatments, corticosteroids, plasma exchange (PE) and haemodialysis (HD). Further, 23 patients had died and 39 had survived within 100 days of hospitalization. Serum creatinine (Cr) was higher in patients who had died vs patients who had survived (P=0.026). Likewise, patients with white blood cells (WBC)≥10 4/μL had higher mortality rate vs patients with WBC<10 4/μL (P=0.039). GMA in patients with WBC≥10 4/μL showed 100% prognosis vs patients with WBC≥10 4/μL who did not receive GMA (P=0.0007). Corticosteroids, PE and HD did not significantly impact prognosis of SAH patients. Conclusions: Our perception is that, patients with elevated myeloid leucocytes benefit most from GMA, while PE appears to support patients with coagulation deficiency or high plasma bilirubin and HD has indication in patients with high Cr.

UR - http://www.scopus.com/inward/record.url?scp=83155180505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83155180505&partnerID=8YFLogxK

U2 - 10.1016/j.clinre.2011.07.005

DO - 10.1016/j.clinre.2011.07.005

M3 - Article

C2 - 21840788

AN - SCOPUS:83155180505

VL - 35

SP - 738

EP - 744

JO - Clinics and Research in Hepatology and Gastroenterology

JF - Clinics and Research in Hepatology and Gastroenterology

SN - 2210-7401

IS - 11

ER -